142 related articles for article (PubMed ID: 37539729)
1. Novel anti‑hepatitis B virus flavonoids sakuranetin and velutin from
Ahmed S; Parvez MK; Al-Dosari MS; Abdelwahid MAS; Alhowiriny TA; Al-Rehaily AJ
Mol Med Rep; 2023 Sep; 28(3):. PubMed ID: 37539729
[TBL] [Abstract][Full Text] [Related]
2. Inter-species comparative antioxidant assay and HPTLC analysis of sakuranetin in the chloroform and ethanol extracts of aerial parts of Rhus retinorrhoea and Rhus tripartita.
Alam P; Parvez MK; Arbab AH; Siddiqui NA; Al-Dosary MS; Al-Rehaily AJ; Ahmed S; Kalam MA; Ahmad MS
Pharm Biol; 2017 Dec; 55(1):1450-1457. PubMed ID: 28345446
[TBL] [Abstract][Full Text] [Related]
3. Novel anti-hepatitis B virus-active catechin and epicatechin from
Parvez MK; Al-Dosari MS; Abdelwahid MAS; Alqahtani AS; Alanzi AR
Exp Ther Med; 2022 Jun; 23(6):398. PubMed ID: 35619632
[TBL] [Abstract][Full Text] [Related]
4. Virological responses to tenofovir-alafenamide-containing antiretroviral therapy in people living with HIV co-infected with lamivudine-resistant or lamivudine-susceptible hepatitis B virus.
Huang YS; Sun HY; Chang SY; Chuang YC; Su YC; Liu WC; Hung CC
Int J Antimicrob Agents; 2022; 60(5-6):106682. PubMed ID: 36279976
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of hepatitis B virus activities by
Parvez MK; Alhowiriny TA; Al-Dosari MS; Amina M; Rehman MT; Al-Yousef HM; Alanzi AR; Alajmi MF
Exp Ther Med; 2023 Jul; 26(1):327. PubMed ID: 37346405
[TBL] [Abstract][Full Text] [Related]
6. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
7. Anti-hepatitis B virus activity of lithospermic acid, a polyphenol from Salvia miltiorrhiza, in vitro and in vivo by autophagy regulation.
Zhu S; Wen H; Wang W; Chen Y; Han F; Cai W
J Ethnopharmacol; 2023 Feb; 302(Pt A):115896. PubMed ID: 36334815
[TBL] [Abstract][Full Text] [Related]
8. Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs.
Huang H; Zhou W; Zhu H; Zhou P; Shi X
Toxicol Appl Pharmacol; 2017 May; 323():36-43. PubMed ID: 28322895
[TBL] [Abstract][Full Text] [Related]
9. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
[TBL] [Abstract][Full Text] [Related]
10. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
11. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
12. [Effects of glycyrrhizin on the expression of hepatitis B virus and Toll like receptors 2,4 in HepG2.2.15 cells expressing low HBsAg].
Li YW; Yang HZ; Ke QS; Chen W; Chen XJ
Zhong Yao Cai; 2008 Mar; 31(3):403-7. PubMed ID: 18619248
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
Chen J; Wang Z; Zhou B; Wang Y; Hou J
Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471
[TBL] [Abstract][Full Text] [Related]
14. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B.
Zhang C; Yang Z; Wang Z; Dou X; Sheng Q; Li Y; Han C; Ding Y
Int J Med Sci; 2020; 17(3):383-389. PubMed ID: 32132873
[No Abstract] [Full Text] [Related]
15. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients.
Chen CH; Hung CH; Wang JH; Lu SN; Hu TH; Lee CM
Clin Microbiol Infect; 2018 Sep; 24(9):997-1003. PubMed ID: 29288020
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
17. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
Wiegand J; Wedemeyer H; Finger A; Heidrich B; Rosenau J; Michel G; Bock CT; Manns MP; Tillmann HL
Antivir Ther; 2008; 13(4):547-54. PubMed ID: 18672533
[TBL] [Abstract][Full Text] [Related]
18. Anti-hepatitis B virus activities of Geranium carolinianum L. extracts and identification of the active components.
Li J; Huang H; Zhou W; Feng M; Zhou P
Biol Pharm Bull; 2008 Apr; 31(4):743-7. PubMed ID: 18379075
[TBL] [Abstract][Full Text] [Related]
19. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
Wooddell CI; Yuen MF; Chan HL; Gish RG; Locarnini SA; Chavez D; Ferrari C; Given BD; Hamilton J; Kanner SB; Lai CL; Lau JYN; Schluep T; Xu Z; Lanford RE; Lewis DL
Sci Transl Med; 2017 Sep; 9(409):. PubMed ID: 28954926
[TBL] [Abstract][Full Text] [Related]
20. Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C.
Xu WZ; Fang Y; Li D; Wang Y; Shang QL; Li GQ; Teng X; Gu HX
World J Gastroenterol; 2008 Jun; 14(23):3733-8. PubMed ID: 18595141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
